Bionic nano vesicle as well as preparation method and application thereof

By integrating PD-1 protein, STING agonist and near-infrared probe into bionic cell membrane vesicles, the problems of limited immunotherapy effects and poor stability of photosensitizers in the prior art were solved, and efficient tumor immunotherapy was achieved, which significantly led to significant results in the tumor immunotherapy. Inhibits tumor growth and improves therapeutic effects.

CN119055616AInactive Publication Date: 2024-12-03THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411569706.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-06
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The effects of immune checkpoint inhibitors in existing cancer immunotherapy are limited, the plasma clearance of STING agonists is fast, the cell membrane permeability is poor, and photosensitizers such as ICG have poor photostability, nonspecific targeting and rapid degradation, which limits tumors. The potential of treatment.

Method used

Integrate PD-1 protein, STING agonist and near-infrared probe into bionic cell membrane vesicles to prepare CDN@PM-ICG, destroy the vesicle structure through photothermal and photodynamic effects, release CDN to activate the STING signaling pathway, and destroy PD- 1/PD-L1 immunosuppressive axis induces dendritic cell maturation and macrophage polarization, and activates CD8+ T cells.

Benefits of technology

It improves the therapeutic effect of TNBC, significantly inhibits tumor growth, enhances immune response, improves the efficiency and targeting of phototherapy, and extends the stability of vesicles and tumor retention time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055616A_ABST
    Figure CN119055616A_ABST
Patent Text Reader

Abstract

The invention discloses a bionic nano-vesicle and a preparation method and application thereof.PD-1 protein, STING agonist and a near-infrared probe are integrated into a bionic cell membrane vesicle, a final product CDN (at) PM-ICG is prepared, after the bionic nano-vesicle is passively targeted to tumor tissue through caudal intravenous injection, photothermal and photodynamic effects can be generated through given laser irradiation, and the tumor tissue can be stimulated to be targeted to the tumor tissue. The PD-1 protein can effectively destroy a PD-1 / PD-L1 immunosuppression axis, ICG-mediated phototherapy can destroy tumor cells, and the released CDN can activate an intracellular STING signal channel and cooperate with phototherapy-mediated ICD, induce maturation of dendritic cells, promote polarization of macrophages to M1 and activate CD8 + T cells, so that the purpose of improving the curative effect of TNBC is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a bionic nanovesicle and a preparation method and application thereof. Background Art

[0002] Cancer immunotherapy is an important progress in the field of oncology in recent years. Among them, immune checkpoint inhibitors (ICIs) have brought significant survival benefits to some cancer patients. As an immune checkpoint receptor, programmed cell death receptor-1 (PD-1) hinders the function of T cell effectors to fight cancer by binding to its main ligand (PD-L1). Tumor immunotherapy based on PD-1 / PD-L1 has been shown to be effective in the treatment of melanoma and triple-negative breast cancer. However, due to insufficient immune activation, such as the inherent low immunogenicity of tumor cells, insufficient or exhausted immune cell infiltration, and the inhibitory tumor immune microenvironment, the response rate of immunotherapy is low. Only 20%~30% of cancer patients can benefit from PD-1 / PD-L1 inhibitors, and some patients will inevitably experience rapid progression and deterioration.

[0003] Studies have shown that the activation of the cyclic GMP-AMPsynthase - Stimulator of interferon genes (cGAS-STING) pathway is closely related to the occurrence and development of tumors, and is generally considered to be an effective regulator of tumor immunity. In addition to the activation of the cGAS-STING pathway in tumor cells, which leads to apoptosis or death of tumor cells, tumor-derived deoxyribonucleic acid (DNA) has also been found in the cytoplasm of tumor-infiltrating dendritic cells, and can activate the cGAS-STING pathway, promote tumor-specific antigen presentation and cytotoxic T lymphocyte (CTL) activation. It is worth noting that Professor Zhijian Chen's team found that the anti-tumor effect of PD-L1 blockers in STING knockout mice was weakened. Therefore, it is believed that the activation of the STING pathway is expected to enhance the therapeutic effect of ICIs. These findings emphasize the important role of the cGAS-STING pathway in tumor immunity. Currently, more and more studies are focused on the synthesis and screening of STING agonists. Among them, the most classic first-generation STING agonists are cyclic dinucleotide (CDN) analogs, but they often face limitations such as rapid plasma clearance, poor cell membrane permeability, and inability to reach the cytoplasm.

[0004] Photoimmunotherapy is a new treatment method that combines phototherapy and immunotherapy. Compared with a single treatment method, this method can significantly improve the treatment effect. Currently, a variety of photosensitizers have been used for photoimmunotherapy. As a photosensitizer, indocyanine green (ICG) can achieve photodynamic therapy (PDT) and photothermal therapy (PTT) under 808 nm near-infrared light irradiation. The tumor immune killing effect includes seven steps: tumor antigen release, antigen presentation, immune system activation, T lymphocyte migration, T lymphocyte infiltration, tumor cell recognition, and tumor cell killing. Tumors with few immune cells and difficult to penetrate are called "cold tumors." ICG has the potential to induce immunogenic cell death (ICD) while providing tumor-specific antigens to kill tumor cells. During the ICD process, tumor cells can activate dendritic cells by releasing a large number of damage-associated molecular patterns (DAMPs), thereby inducing anti-tumor immune responses, initiating a cascade process, and leading to antigen-specific T cell responses. However, ICG has some disadvantages, such as poor photostability, weak photothermal capacity, nonspecific targeting, and rapid degradation and clearance in living tissues, which limit its potential in tumor treatment.

[0005] Among the possible strategies to address these challenges, cell membrane-derived nanovesicles (NVs) provide a promising drug delivery solution. Due to their biophysical properties, cell membrane-derived nanovesicles such as exosomes, macrovesicles, and membrane-extruded vesicles have great potential in drug delivery. They have good biocompatibility, low toxicity, and low immunogenicity, thus playing a vital role in intercellular communication. Summary of the invention

[0006] In order to address the shortcomings of the prior art, the present invention provides a bionic nanovesicle and a preparation method and application thereof, integrating PD-1 protein, STING agonist and near-infrared probe into bionic cell membrane vesicles to obtain the final product CDN@PM-ICG.

[0007] The technical solution adopted by the present invention is: a bionic nanovesicle, which is composed of a cell membrane and PD-1 protein, a STING agonist and a photosensitizer, wherein the cell membrane and the PD-1 protein are the cell membranes of cells expressing PD-1, and the STING agonist is a cyclic dinucleotide (CDN) analogue.

[0008] The cyclic dinucleotide (CDN) analog is the STING agonist 2',3'-cGAMP.

[0009] The photosensitizer is indocyanine green (ICG).

[0010] The cells expressing PD-1 are HEK 293T cells expressing PD-1.

[0011] The bionic nanovesicles are obtained by loading the cell membrane of HEK 293T cells expressing PD-1 with photosensitizer indocyanine green (ICG) and STING agonist 2',3'-cGAMP.

[0012] A method for preparing bionic nanovesicles comprises the following steps: S1. constructing a lentivirus containing the PD-1 gene, transfecting HEK 293T cells with the lentivirus, screening the successfully transfected cells after culture, obtaining a stable expression system of the PD-1 protein, culturing the HEK 293T cells stably expressing the PD-1 protein, and collecting these cells; S2, resuspend the cells in homogenization medium (HM) with Hepes-NaOH, EDTA, sucrose and protease inhibitors at pH 7.4, then ultrasonically disrupt on ice, centrifuge to obtain cell membrane fragments, and filter with STING agonist multiple times; filter through 0.8 μm filter at least 10 times, and then filter through 0.22 μm filter at least 10 times; S3. The cell membrane fragments and STING agonist vesicles obtained by ICG and S2 were stirred overnight and filtered again multiple times before co-extrusion to obtain biomimetic membrane nanovesicles.

[0013] The multiple filtration in step S2 is first filtering through a 0.8 μm filter at least 10 times, and then filtering through a 0.22 μm filter at least 10 times.

[0014] The multiple filtrations followed by co-extrusion in step S3 are performed by filtering through 0.8 μm and 0.22 μm and then co-extruding.

[0015] Application of bionic nanovesicles in the preparation of photoimmunotherapy drugs for tumors.

[0016] The beneficial effects of the present invention are as follows: the present invention provides a bionic nanovesicle and a preparation method and application thereof. The present invention integrates PD-1 protein, STING agonist and near-infrared probe into bionic cell membrane vesicles to obtain the final product CDN@PM-ICG. The bionic nanovesicle is injected into the tail vein. After passively targeting the tumor tissue, the laser irradiation will cause it to produce photothermal and photodynamic effects, destroy the vesicle structure, and release CDN, wherein the PD-1 protein can effectively destroy the PD-1 / PD-L1 immunosuppressive axis, and ICG-mediated phototherapy can destroy tumor cells. The released CDN will activate the intracellular STING signaling pathway and cooperate with phototherapy-mediated ICD, induce dendritic cell maturation, promote macrophage polarization to M1, and activate CD8 + T cells, thereby achieving the goal of improving the efficacy of TNBC. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 (a) Preparation of CDN@PM-ICG biomimetic nanovesicles; (b) Schematic diagram of synergistic cancer immunotherapy mediated by CDN@PM-ICG biomimetic nanovesicles.

[0018] Figure 2 (ac) TEM images and particle size distribution of PD-1 NVs, CDN@PM, and CDN@PM-ICG; (d) Zeta potential of PD-1 NVs, CDN@PM, and CDN@PM-ICG.

[0019] Figure 3 (a) UV-visible spectra of ICG, CDN@PM and CDN@PM-ICG aqueous solutions; (b) fluorescence spectra of ICG, CDN@PM and CDN@PM-ICG aqueous solutions.

[0020] Figure 4 (a) Standard curve of CDN solution; (b) Standard curve of ICG solution.

[0021] Figure 5 The changes in particle size and PDI of CDN@PM-ICG within 72 h.

[0022] Figure 6 Comparison of the normalized degradation rate (A / A0) of DPBF in PD-1 NVs, ICG, CDN@PM, and CDN@PM-ICG solutions before and after laser irradiation.

[0023] Figure 7 (a) Infrared thermal image under in vitro laser irradiation; (b) Temperature curve under in vitro laser irradiation.

[0024] Figure 8The phototoxicity of CDN, ICG, CDN@PM and CDN@PM-ICG on 4T1 cells; the symbols “+” and “-” represent laser irradiation and no laser irradiation, respectively.

[0025] Fig. 9 (a) Real-time near-infrared fluorescence images of 4T1 tumor-bearing mice at different time points after intravenous administration of ICG or CDN@PM-ICG. The black circles represent the local areas within the tumor. (b) Changes in fluorescence intensity in the tumor area over time.

[0026] Fig.10 (a) Ex vivo near-infrared fluorescence images of mouse tissues (from top to bottom: heart, liver, spleen, lung, kidney, and tumor) after administration of ICG or CDN@PM-ICG; (b) quantitative analysis of fluorescence signals of ex vivo organs and tumor tissues.

[0027] Fig.11 (a) In-vivo infrared thermal imaging under laser irradiation; (b) In-vivo temperature curve under laser irradiation.

[0028] Fig.12 (a) Schematic diagram of the synergistic photoimmunotherapy protocol for mice with unilateral subcutaneous 4T1 breast tumors; (b) Average tumor growth kinetics of 4T1 tumor-bearing mice in different treatment groups; (c) Individual tumor growth kinetics of 4T1 tumor-bearing mice in different treatment groups; the symbol “+” indicates laser irradiation.

[0029] Fig.13 Representative photos of 4T1 tumor-bearing mice before treatment (day 0), during treatment (day 9), and at the end of treatment (day 18). The symbol “+” indicates laser irradiation.

[0030] Fig.14 (a) After treatment, the tumor weights of 4T1 tumor-bearing mice in different treatment groups were collected; (b) After treatment, the tumor photos of 4T1 tumor-bearing mice in different treatment groups were collected; the symbol “+” indicates laser irradiation. DETAILED DESCRIPTION

[0031] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] Example 1: Preparation of biomimetic nanovesicles CDN@PM-ICG.

[0033] A lentivirus containing the PD-1 gene was constructed and used to transfect HEK 293T cells. After culturing for 24 h, the cells were screened for drug resistance with puromycin to obtain a stable expression line of PD-1 protein. HEK 293T cells stably expressing PD-1 protein were cultured in complete medium and collected. Then, the cells were resuspended in homogenization medium (HM) containing 20 mM Hepes-NaOH, 1 mM EDTA, 0.25 mM sucrose and protease inhibitors at pH 7.4. After that, the cells were disrupted on ice by an ultrasonic disruptor (Sonics VCX500) at 40% power for 5 min. After centrifugation to obtain cell membrane fragments and STING agonist 2',3'-cGAMP, they were passed through a 0.8 μm filter at least 10 times, and then through a 0.22 μm filter at least 10 times. Finally, ICG and nanovesicles were stirred overnight and coextruded through 0.8 μm and 0.22 μm filters again to obtain biomimetic membrane nanovesicles, named CDN@PM-ICG.

[0034] Embodiment 2: CDN@PM can be obtained by co-extrusion of CDN and PD-1 NVs, and then CDN@PM-ICG can be obtained by mixing with ICG. TEM observations show that PD-1 NVs are closed spherical nanovesicles ( Figure 2 a) with good dispersibility. DLS measurements showed that the hydrated particle size of PD-1 NVs was about 130 nm and the Zeta potential was about -30 mV ( Figure 2 d). With the addition of CDN and ICG, the particle size of the prepared CDN@PM-ICG gradually increased and reached about 166 nm ( Figure 2 b-2c), because CDN and ICG are negatively charged, the Zeta potential gradually decreases ( Figure 2 d) This indirectly confirms the successful loading of CDN and ICG.

[0035] Embodiment 3: By analyzing the UV-visible spectra of different solutions, we found that CDN@PM had no obvious absorption peak; ICG and CDN@PM-ICG had similar characteristic absorption peaks, which also showed that CDN@PM-ICG had the same strong photothermal conversion ability as ICG in the near-infrared region ( Figure 3 a). In addition, fluorescence spectroscopy analysis showed that the fluorescence signal emitted by CDN@PM was negligible; in contrast, ICG and CDN@PM-ICG showed enhanced fluorescence intensity ( Figure 3 b).

[0036] Embodiment 4: We used HPLC and UV-visible spectroscopy to quantify CDN and ICG in CDN@PM-ICG. Figure 4 a and Figure 4 b are the standard curves of CDN and ICG, respectively. The results show that the encapsulation efficiency of CDN is 87.76% and that of ICG is 22.24%.

[0037] Embodiment 5: like Figure 5 As shown in the figure, the particle size and polydispersity index (PDI) of CDN@PM-ICG did not change significantly over time, indicating that CDN@PM-ICG has long-term stability.

[0038] Embodiment 6: The mechanism of action of photodynamic therapy (PDT) involves the consumption of intracellular oxygen to produce toxic singlet oxygen that kills cells, thereby exacerbating cellular hypoxia. 1 O2 sensitive probe DPBF was used to study the laser-induced 1 The production of O2. Figure 6 As shown, the changes in the UV-visible absorption intensity at 419 nm of DPBF treated with PD-1 NVs or CDN@PM alone were negligible, indicating that they could not produce 1 O2, while the UV-visible absorption intensity of DPBF treated with ICG and CDN@PM-ICG showed time dependence.

[0039] Embodiment 7: Infrared thermal imaging analysis shows that the power density is 1.0W / cm 2 After laser irradiation, the temperature of the CDN@PM-ICG solution increased from 24.5°C to 53.0°C, with no significant magnitude difference compared to ICG alone. This indicates that the co-loading of PD-1 NVs and CDN does not affect the photothermal conversion performance of ICG ( Figure 7 a and 7b).

[0040] Embodiment 8: To verify the synergistic cytotoxic effect of CDN@PM-ICG under laser irradiation, we performed CCK-8 experiments to evaluate the inhibitory effect of CDN@PM-ICG on tumor cell proliferation. Figure 8 As shown, under laser irradiation, both ICG and CDN@PM-ICG exhibited a concentration-dependent increase in cytotoxicity, which was due to the ICG-induced cell killing effect under light irradiation.

[0041] Embodiment 9: In order to optimize the phototherapy effect, fluorescence imaging was used to guide the illumination, which enabled ICG-based phototherapy to have more parameter adjustment capabilities while minimizing potential systemic toxic side effects. We used the PerkinElmer IVIS imaging system and ICG as a near-infrared fluorescent probe to observe the tissue distribution of ICG after intravenous administration in mice. The results showed that the fluorescence signal intensity at the tumor site in the CDN@PM-ICG group gradually increased over time, reaching a peak at 8 h after injection, and was significantly higher than that in the ICG group ( Fig. 9 a and 9b).

[0042] Embodiment 10: At the end of the monitoring period (24 h), all mice were euthanized, and the main organs and tumor tissues of tumor-bearing mice were removed for ex vivo fluorescence imaging. Fig.10 As shown in Figures 10a and 10b, after 24 h of monitoring, the fluorescence intensity of the CDN@PM-ICG group in the tumor was 2.89 times that of the free ICG group, indicating that CDN@PM-ICG has good tumor retention and tumor accumulation capabilities.

[0043] Embodiment 11: After 8 h of intravenous administration of each dosage form, the tumor site of the mice was irradiated with a power intensity of 1.0 W / cm 2 The near-infrared radiation was irradiated, and the temperature change of the tumor area was observed by infrared thermal imager. The results showed that the local tumor temperature of mice in the PBS group did not increase significantly, while the ICG group and CDN@PM-ICG group showed a significant temperature increase under laser irradiation ( Fig.11 a). In addition, the tumor site temperature of mice in the CDN@PM-ICG group rapidly increased to 53.4°C, which was significantly higher than the peak tumor site temperature of the ICG group (39.8°C) ( Fig.11 b). The results show that CDN@PM-ICG has a remarkable photothermal conversion efficiency in vivo.

[0044] Embodiment 12: In mice bearing unilateral subcutaneous 4T1 breast tumors, we further evaluated the inhibitory effect of CDN@PM-ICG-mediated synergistic photoimmunotherapy on tumor growth. The 4T1 tumor-bearing mice were divided into five groups. After tumor appearance, intravenous administration was performed at a specific time. Eight hours after intravenous injection, the tumor sites of the mice in the laser irradiation group were laser irradiated ( Fig.12 a). After various treatments, the efficacy of all mice was evaluated by measuring the size of the tumor every two days. Fig.12As shown in Figure b, compared with the control group, the other four groups had certain therapeutic effects, but the ICG+laser group, CDN@PM+laser group, and CDN@PM-ICG group only showed weak tumor inhibition. In contrast, the CDN@PM-ICG+laser group had a significant therapeutic effect, with a tumor growth inhibition rate of 90.7%. In addition, we also plotted the tumor growth curve of each mouse to intuitively monitor tumor growth. Fig.12 As shown in c, the tumor growth of mice treated with CDN@PM-ICG+laser was significantly inhibited or even disappeared after the treatment cycle ended (day 18), while obvious tumor growth was observed in other groups.

[0045] Embodiment 13: The present invention also takes photos of each group of mice before treatment (day 0), during treatment (day 9) and at the end of treatment (day 18) ( Fig.13 ). It can be observed that the tumor growth of mice in the CDN@PM-ICG+laser group was not obvious after the treatment cycle was completed, while obvious tumor growth was observed in all other treatment groups, indicating that the CDN@PM-ICG+laser group had a significant therapeutic effect.

[0046] Embodiment 14: At the end of the treatment period (day 18), all mice were euthanized and the tumors of mice in each group were collected and weighed. Fig.14 As shown in a, the control group showed consistent results with the above findings, showing rapid tumor growth. A reduction in tumor weight was observed in the ICG+laser group, the CDN@PM+laser group, and the CDN@PM-ICG group. Compared with the other treatment groups, the CDN@PM-ICG+laser group showed a significantly reduced tumor weight, indicating a superior therapeutic effect. At the same time, we also took pictures of the tumors in each group to evaluate the overall efficacy ( Fig.14 b). Tumor images showed that the tumor in the control group was significantly enlarged, while the tumor size in the ICG+laser group, CDN@PM+laser group, and CDN@PM-ICG group was slightly smaller than that in the control group, indicating a weaker therapeutic effect. In contrast, tumor growth in the CDN@PM-ICG+laser group was significantly inhibited, and tumor volume was significantly reduced.

[0047] The above are only preferred embodiments of the present invention, and the protection scope of the present invention is not limited to the above embodiments. All technical solutions under the concept of the present invention belong to the protection scope of the present invention. It should be pointed out that for ordinary technicians in this technical field, some improvements and modifications without departing from the principle of the present invention should be regarded as the protection scope of the present invention.

[0048] Technical personnel should note that although the present invention has been described according to the above specific implementation methods, the inventive concept of the present invention is not limited to this invention, and any modification using the inventive concept will be included in the scope of protection of this patent.

Claims

1. A bionic nanovesicle, characterized in that: The bionic nanovesicles are composed of cell membranes and PD-1 proteins, STING agonists and photosensitizers, wherein the cell membranes and PD-1 proteins are the cell membranes of cells expressing PD-1, and the STING agonist is a cyclic dinucleotide (CDN) analog.

2. A biomimetic nanovesicle according to claim 1, characterized in that: The cyclic dinucleotide (CDN) analog is the STING agonist 2',3'-cGAMP.

3. A biomimetic nanovesicle according to claim 2, characterized in that: The photosensitizer is indocyanine green (ICG).

4. A biomimetic nanovesicle according to claim 3, characterized in that: The cells expressing PD-1 are HEK 293T cells expressing PD-1.

5. The biomimetic nanovesicle according to claim 4, characterized in that: The bionic nanovesicles are obtained by loading the cell membrane of HEK 293T cells expressing PD-1 with photosensitizer indocyanine green (ICG) and STING agonist 2',3'-cGAMP.

6. A method for preparing the bionic nanovesicles according to claim 1, characterized in that: The following steps are involved: S1. constructing a lentivirus containing the PD-1 gene, transfecting HEK 293T cells with the lentivirus, screening the successfully transfected cells after culture, obtaining a stable expression system of the PD-1 protein, culturing the HEK 293T cells stably expressing the PD-1 protein, and collecting these cells; S2, resuspend the cells in homogenization medium (HM) with Hepes-NaOH, EDTA, sucrose and protease inhibitors at pH 7.4, then ultrasonically disrupt on ice, centrifuge to obtain cell membrane fragments, and filter with STING agonist multiple times; filter through 0.8 μm filter at least 10 times, and then filter through 0.22 μm filter at least 10 times; S3. The cell membrane fragments and STING agonist vesicles obtained by ICG and S2 were stirred overnight and filtered again multiple times before co-extrusion to obtain biomimetic membrane nanovesicles.

7. The preparation method according to claim 6, characterized in that: The multiple filtration in step S2 is first filtering through a 0.8 μm filter at least 10 times, and then filtering through a 0.22 μm filter at least 10 times.

8. The preparation method according to claim 6, characterized in that: The multiple filtrations followed by co-extrusion in step S3 are performed by filtering through 0.8 μm and 0.22 μm and then co-extruding.

9. Use of the bionic nanovesicles according to claim 1 in preparing photoimmunotherapy drugs for tumors.

Citation Information

Patent Citations

  • Bionic cell membrane nanoparticle as well as preparation method and application thereof

    CN112972420A

  • Nano vesicle jointly loaded with PD-L1 antibody and STING agonist as well as preparation method and application thereof

    CN113521303A

  • Genetically engineered cell membrane coating liposome nano-vesicle as well as preparation and application thereof

    CN115120572A

  • Cell membrane bionic nano-vesicle for expressing transferrin as well as preparation method and application of cell membrane bionic nano-vesicle

    CN116144600A